成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 112887-68-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 112887-68-0
Chemical Structure| 112887-68-0
Structure of 112887-68-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 112887-68-0 ]

Related Doc. of [ 112887-68-0 ]

Alternatived Products of [ 112887-68-0 ]
Product Citations

Product Details of [ 112887-68-0 ]

CAS No. :112887-68-0 MDL No. :
Formula : C21H22N4O6S Boiling Point : -
Linear Structure Formula :- InChI Key :IVTVGDXNLFLDRM-HNNXBMFYSA-N
M.W : 458.49 Pubchem ID :135400182
Synonyms :
ZD 1694; TDX; D-1694; ICI-D1694
Chemical Name :(S)-2-(5-(Methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid

Calculated chemistry of [ 112887-68-0 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 32
Num. arom. heavy atoms : 15
Fraction Csp3 : 0.29
Num. rotatable bonds : 10
Num. H-bond acceptors : 7.0
Num. H-bond donors : 4.0
Molar Refractivity : 119.67
TPSA : 180.93 ?2

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -8.09 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.94
Log Po/w (XLOGP3) : 1.42
Log Po/w (WLOGP) : 1.83
Log Po/w (MLOGP) : 1.05
Log Po/w (SILICOS-IT) : 3.18
Consensus Log Po/w : 1.88

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 1.0
Bioavailability Score : 0.11

Water Solubility

Log S (ESOL) : -3.26
Solubility : 0.25 mg/ml ; 0.000544 mol/l
Class : Soluble
Log S (Ali) : -4.82
Solubility : 0.00687 mg/ml ; 0.000015 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.01
Solubility : 0.00448 mg/ml ; 0.00000977 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.77

Safety of [ 112887-68-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 112887-68-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 112887-68-0 ]

[ 112887-68-0 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 132463-02-6 ]
  • [ 112887-68-0 ]
YieldReaction ConditionsOperation in experiment
80% With sodium hydroxide In water at 25℃; To the reaction flask, 1.35 g of sodium hydroxide and 3.3 ml of water were added, and the mixture was cooled to 25 °C or lower, and 1.35 g of the starting material (Compound 2) was slowly added with stirring. The mixture was further stirred for 1.5 to 2 hours, and then the reaction solution (2 × 27ml), water phase filtration. The filtrate was stirred with 2M hydrochloric acid to adjust the pH to 3.0, and the mixture was stirred for 2 hours. The product was washed with distilled water and the solid was dried under vacuum at 80 °C for 10 hours to give 0.96 g of product, 80percent yield and 99.5percent HPLC purity.
80.6% at 20℃; for 2 h; 340.0 g of N-[[5-[N-(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)-methyl]-N-methyl]Amino-2-thiophenecarbonyl]-L-glutamic acid diethyl ester was added in portions to a 3N sodium hydroxide solution (6500 ml) and the reaction was stirred at room temperature for 2 hours. TLC monitored the progress of the reaction. After the reaction was completed, the pH was adjusted to 3 to 4 with 3N hydrochloric acid, the crystals were further stirred for 1 hour, and suction filtered to give a yellow solid. Recrystallization from methanol-water (4:1) gave 244.2 g of a pale yellow solid, namely raltitrexed, with a yield of 80.6percent, an HPLC purity of 99.8percent,
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Patent: CN106957296, 2017, A, . Location in patent: Paragraph 0064; 0065
[3] Patent: CN107616976, 2018, A, . Location in patent: Paragraph 0090; 0091
[4] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 2
  • [ 112889-02-8 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN107616976, 2018, A,
  • 3
  • [ 106585-63-1 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN106957296, 2017, A,
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN106957296, 2017, A,
[5] Patent: CN106957296, 2017, A,
[6] Patent: CN107616976, 2018, A,
  • 4
  • [ 106585-64-2 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN106957296, 2017, A,
[3] Patent: CN106957296, 2017, A,
[4] Patent: CN106957296, 2017, A,
[5] Patent: CN106957296, 2017, A,
[6] Patent: CN107616976, 2018, A,
  • 5
  • [ 112888-43-4 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 6
  • [ 132463-33-3 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 7
  • [ 39978-57-9 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
[2] Patent: CN107616976, 2018, A,
  • 8
  • [ 1118-89-4 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 9
  • [ 132463-32-2 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 10
  • [ 131052-68-1 ]
  • [ 112887-68-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1991, vol. 34, # 5, p. 1594 - 1605
  • 11
  • [ 16450-41-2 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
[2] Patent: CN107616976, 2018, A,
  • 12
  • [ 4282-31-9 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
  • 13
  • [ 651295-42-0 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
  • 14
  • [ 651295-44-2 ]
  • [ 112887-68-0 ]
Reference: [1] Synthetic Communications, 2003, vol. 33, # 20, p. 3519 - 3526
  • 15
  • [ 527-72-0 ]
  • [ 112887-68-0 ]
Reference: [1] Patent: CN107616976, 2018, A,
[2] Patent: CN107616976, 2018, A,
  • 16
  • [ 6317-37-9 ]
  • [ 112887-68-0 ]
Reference: [1] Patent: CN107616976, 2018, A,
[2] Patent: CN107616976, 2018, A,
  • 17
  • [ 5751-84-8 ]
  • [ 112887-68-0 ]
Reference: [1] Patent: CN107616976, 2018, A,
  • 18
  • [ 67318-11-0 ]
  • [ 112887-68-0 ]
Reference: [1] Patent: CN107616976, 2018, A,
Recommend Products
Same Skeleton Products
Historical Records
; ;